Jacobson Pharma Corporation Limited (HKG:2633)

Market Cap	2.30B
Revenue (ttm)	1.56B
Net Income (ttm)	253.22M
Shares Out	1.99B
EPS (ttm)	0.13
PE Ratio	8.97
Forward PE	n/a
Dividend	0.07 (5.98%)
Ex-Dividend Date	Feb 25, 2025

Volume	344,000
Average Volume	1,014,223
Open	1.160
Previous Close	1.170
Day's Range	1.160 - 1.180
52-Week Range	0.550 - 1.370
Beta	0.32
RSI	44.36
Earnings Date	Feb 20, 2025

About HKG:2633

Jacobson Pharma Corporation Limited, through its subsidiaries, develops, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including gastrointestinal disorders, cardiovascular conditions, inflammatory and autoimmune diseases, multiple myeloma treatment, oncology, breast cancer therapy, central nervous system, respiratory, oral antidiabetics, musculo-skeletal, genito-urinary, anti-infe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 1,723
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2633

Financial Performance

In 2023, HKG:2633's revenue was 1.47 billion, an increase of 15.79% compared to the previous year's 1.27 billion. Earnings were 266.97 million, an increase of 6.34%.